We have shown that ATP10A is required to maintain lipid homeostasis and liver insulin sensitivity with HFD feeding, therefore, a therapeutic that acts as an ATP10A agonist could help treat diseases that cause dyslipidemia and hepatic insulin resistance. Here, ATP10A is linked to metabolic syndrome.